StreetInsider.com News Articles

AIAI Holdings extends lock-up agreements, pushing share release to 2027

Fri, 11 Sep 2026 08:33:53 -0400

AIAI Holdings Corporation (NASDAQ: AIAI) has amended its existing lock-up agreements with key shareholders, extending restrictions on the sale of shares originally tied to the company's direct listing.

The amended agreements were signed by the company's founder and chairman, other board members, members of management, and a majority of its largest stockholders.

Under the revised schedule, restrictions on 70% of the currently locked shares will remain in place until mid-February 2027, when the restricted portion drops to 50%. Restrictions then decline to 30% in mid-March 2027, with the remaining 30% released entirely by mid-April 2027.

Todd Furniss, Chief Executive Officer and Co-Founder of

AIAI Holdings Enters into Extended Lock-up Agreements to Protect Long-Term Stockholder Value

Fri, 11 Sep 2026 08:30:00 -0400

DALLAS, TX / ACCESS Newswire / September 11, 2026 / AIAI Holdings Corporation (NASDAQ:AIAI) ("Ai²" or the "Company"), an AI-enabled diversified holding company utilizing Transformational AI (TAI) to enhance portfolio performance announced today that it has entered into amendments to its existing lock-up agreements entered into in connection with the Company's direct listing with holders of the Company's outstanding shares of Class A Common Stock. The list of those signing the amendment includes the Company's founder and Chairman, other members of the Company's board of directors, members of management and

AIAI Holdings Enters into Extended Lock-up Agreements to Protect Long-Term Stockholder Value

Fri, 11 Sep 2026 08:30:00 -0400

Peer-Reviewed Study Published in MDPI’s AI Journal Shows NetraAI Uncovers Clinical Trial Signals Missed by Conventional AI and Foundation Models

Thu, 10 Sep 2026 07:00:00 -0400

NetraAI’s biological and clinical signatures successfully boosted the accuracy of all eight evaluated algorithms across every single dataset tested
The study showed improved performance across conventional machine learning, neural-network and foundation-model (including Fable 5) approaches in schizophrenia, major depressive disorder and pancreatic cancer
Findings support what the company believes is the potential of an unbiased discovery-first approach to uncover clinically relevant structure in complex trial data and inform future patient-stratification and trial-enrichment strategies

TORONTO, Sept. 10, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the "Company" or "NetraMark") (TSX: AIAI) (OTCQB: AINMF) (Frankfurt:

Peer-Reviewed Study Published in MDPI’s AI Journal Shows NetraAI Uncovers Clinical Trial Signals Missed by Conventional AI and Foundation Models

Thu, 10 Sep 2026 07:00:00 -0400

NetraAI’s biological and clinical signatures successfully boosted the accuracy of all eight evaluated algorithms across every single dataset tested
The study showed improved performance across conventional machine learning, neural-network and foundation-model (including Fable 5) approaches in schizophrenia, major depressive disorder and pancreatic cancer
Findings support what the company believes is the potential of an unbiased discovery-first approach to uncover clinically relevant structure in complex trial data and inform future patient-stratification and trial-enrichment strategies

TORONTO, Sept. 10, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the "Company" or "NetraMark") (TSX: AIAI) (OTCQB: AINMF) (Frankfurt:

Peer-Reviewed Study Published in MDPI’s AI Journal Shows NetraAI Uncovers Clinical Trial Signals Missed by Conventional AI and Foundation Models

Thu, 10 Sep 2026 07:00:00 -0400

NetraAI’s biological and clinical signatures successfully boosted the accuracy of all eight evaluated algorithms across every single dataset tested
The study showed improved performance across conventional machine learning, neural-network and foundation-model (including Fable 5) approaches in schizophrenia, major depressive disorder and pancreatic cancer
Findings support what the company believes is the potential of an unbiased discovery-first approach to uncover clinically relevant structure in complex trial data and inform future patient-stratification and trial-enrichment strategies

TORONTO, Sept. 10, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the "Company" or "NetraMark") (TSX: AIAI) (OTCQB: AINMF) (Frankfurt:

Peer-Reviewed Study Published in MDPI’s AI Journal Shows NetraAI Uncovers Clinical Trial Signals Missed by Conventional AI and Foundation Models

Thu, 10 Sep 2026 07:00:00 -0400

NetraAI’s biological and clinical signatures successfully boosted the accuracy of all eight evaluated algorithms across every single dataset tested
The study showed improved performance across conventional machine learning, neural-network and foundation-model (including Fable 5) approaches in schizophrenia, major depressive disorder and pancreatic cancer
Findings support what the company believes is the potential of an unbiased discovery-first approach to uncover clinically relevant structure in complex trial data and inform future patient-stratification and trial-enrichment strategies

TORONTO, Sept. 10, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the "Company" or "NetraMark") (TSX: AIAI) (OTCQB: AINMF) (Frankfurt:

NetraMark appoints Kevin Felix as strategic advisor

Tue, 08 Sep 2026 07:00:49 -0400

NetraMark Holdings Inc. (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) has appointed Kevin Felix as Strategic Advisor, according to a company statement released Sept. 8, 2026.

Felix brings more than 25 years of senior leadership experience in capital markets, asset management, corporate strategy and securities law. He most recently served as President of the Investment Office at Global Atlantic Financial Group, where he oversaw business management and operational matters related to the firm's $175 billion investment portfolio.

Prior to that role, Felix held senior positions at Scotiabank, including President and CEO of Scotia Capital (USA) Inc. and Global Head of Fixed Income, Currencies,

NetraMark appoints Kevin Felix as strategic advisor

Tue, 08 Sep 2026 07:00:49 -0400

NetraMark Holdings Inc. (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) has appointed Kevin Felix as Strategic Advisor, according to a company statement released Sept. 8, 2026.

Prior to that role, Felix held senior positions at Scotiabank, including President and CEO of Scotia Capital (USA) Inc. and Global Head of Fixed Income, Currencies,

NetraMark Appoints Former Global Atlantic Investment Office President and Scotiabank U.S. CEO Kevin Felix as Strategic Advisor

Tue, 08 Sep 2026 07:00:00 -0400

Veteran global finance leader adds institutional investment, capital markets and strategic transaction expertise to NetraMark

TORONTO, Sept. 08, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the "Company" or "NetraMark") (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), a clinical intelligence company transforming clinical trials with AI-powered precision analytics in the pharmaceutical industry, today announced the appointment of Kevin Felix as Strategic Advisor, strengthening the senior strategic and institutional experience surrounding the Company as NetraMark advances its commercialization strategy.

Mr. Felix brings more than 25 years of senior leadership experience across capital

NetraMark Appoints Former Global Atlantic Investment Office President and Scotiabank U.S. CEO Kevin Felix as Strategic Advisor

Tue, 08 Sep 2026 07:00:00 -0400

Veteran global finance leader adds institutional investment, capital markets and strategic transaction expertise to NetraMark

Mr. Felix brings more than 25 years of senior leadership experience across capital

AIAI Holdings signs LOI to acquire defense firm from affiliated entity

Thu, 03 Sep 2026 08:31:25 -0400

AIAI Holdings Corporation (NASDAQ: AIAI) has signed a letter of intent to acquire a controlling interest in a defense industry business held by Messier 42 LLC, an affiliated entity of the company, according to a press release dated September 3, 2026.

The transaction is expected to close as early as the fourth quarter of 2026. Messier 42 LLC projects the acquired business will generate $250 million in free cash flow in the 12 months following the closing. The company said the deal is expected to be accretive to AIAI stockholders.

Because of the related-party nature of the transaction, AIAI is required to

AIAI Holdings Announces Letter of Intent with Messier 42 LLC to Acquire Controlling Interest in Defense & National Security Company

Thu, 03 Sep 2026 08:30:00 -0400

With Projected $250M of Annual Free Cash Flow Post Closing

DALLAS, TX / ACCESS Newswire / September 3, 2026 / AIAI Holdings Corporation (NASDAQ:AIAI) ("Ai²" or the "Company"), an AI-enabled diversified holding company utilizing Transformational AI (TAI) to enhance portfolio performance, announced that the Company has entered into a letter of intent with its affiliated entity, Messier 42 LLC ("M42"), to acquire a controlling interest in one of M42's businesses with operations in the defense industry.

M42 projects that this business is expected to produce $250 million in Free Cash Flow

AIAI Holdings Announces Letter of Intent with Messier 42 LLC to Acquire Controlling Interest in Defense & National Security Company

Thu, 03 Sep 2026 08:30:00 -0400

With Projected $250M of Annual Free Cash Flow Post Closing

M42 projects that this business is expected to produce $250 million in Free Cash Flow

NetraMark Strengthens Board of Directors with Appointment of Veteran Pharmaceutical Executive Dr. Keith Fournier

Tue, 01 Sep 2026 07:00:00 -0400

TORONTO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the "Company" or "NetraMark") (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), a clinical intelligence company transforming clinical trials with AI-powered precision analytics in the pharmaceutical industry, announced today the appointment of Dr. Keith M. Fournier, PhD, RAC, to its Board of Directors.

Dr. Fournier is a highly experienced pharmaceutical executive with more than two decades of leadership across drug development, global regulatory strategy and cross-functional portfolio management. His career has spanned the development lifecycle from Investigational New Drug (IND) activities through global

NetraMark Strengthens Board of Directors with Appointment of Veteran Pharmaceutical Executive Dr. Keith Fournier

Tue, 01 Sep 2026 07:00:00 -0400

NetraMark to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

Thu, 27 Aug 2026 07:00:00 -0400

Virtual corporate presentation available September 11, 2026
NetraMark management to hold in-person one-on-one investor meetings in New York City September 14th and 15th

TORONTO, Aug. 27, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the "Company" or "NetraMark") (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), a clinical intelligence company transforming clinical trials with AI-powered precision analytics in the pharmaceutical industry, today announced its participation in the H.C. Wainwright 28th Annual Global Investment Conference.